Psychemedics Corporation (NASDAQ:PMD) is expected to pay $0.15 on Nov 17, 2016. The indicated annual dividend is $0.60. Shareholders owning the stock before Nov 3, 2016 will be eligible to receive the payout. Based on Psychemedics Corporation’s current price of $22.86, the dividend is 0.66%. This dividend’s record date is Nov 7, 2016 and the announcement date is Oct 27, 2016. The stock closed at $22.86 during the last session. It is down 66.25% since March 31, 2016 and is uptrending. It has outperformed by 63.73% the S&P500.
Psychemedics Corporation provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The company has a market cap of $121.52 million. The Firm operates in drug testing services segment. It has a 27.85 P/E ratio. The Firm is in the business of performing drug testing and reporting the results thereof.
Insitutional Activity: The institutional sentiment decreased to 0.69 in 2016 Q2. Its down 0.17, from 0.86 in 2016Q1. The ratio worsened, as 1 funds sold all Psychemedics Corp. shares owned while 12 reduced positions. 3 funds bought stakes while 6 increased positions. They now own 2.80 million shares or 2.25% less from 2.87 million shares in 2016Q1.
Wall Street Access Asset Mgmt reported 134,838 shares or 1.12% of all its holdings. Punch And Associate Management accumulated 0.15% or 95,360 shares. Connors Investor has invested 0.03% of its portfolio in Psychemedics Corp. (NASDAQ:PMD). Blackrock Ltd holds 0% of its portfolio in Psychemedics Corp. (NASDAQ:PMD) for 2,424 shares. Dimensional Fund Advisors L P last reported 0% of its portfolio in the stock. Retail Bank Of America Corp De reported 18,095 shares or 0% of all its holdings. Kennedy Management Incorporated accumulated 0.05% or 168,823 shares. Winslow Evans And Crocker Incorporated has invested 0% of its portfolio in Psychemedics Corp. (NASDAQ:PMD). Granite Inv accumulated 0.13% or 119,027 shares. Deprince Race And Zollo reported 36,497 shares or 0.01% of all its holdings. Federated Invsts Inc Pa reported 112 shares or 0% of all its holdings. Blackrock Institutional Tru Co Na holds 0% or 15,776 shares in its portfolio. Deutsche Retail Bank Ag, a Germany-based fund reported 30,370 shares. The New York-based Renaissance Tech Lc has invested 0.01% in Psychemedics Corp. (NASDAQ:PMD). Northern Trust last reported 0% of its portfolio in the stock.
More notable recent Psychemedics Corp. (NASDAQ:PMD) news were published by: Seekingalpha.com which released: “Psychemedics: Brazil Expansion Story Continues To Play Out” on October 31, 2016, also Quotes.Wsj.com with their article: “Psychemedics Corp. PMD (US: Nasdaq)” published on February 12, 2011, Reuters.com published: “BRIEF-Psychemedics Corp quarterly earnings per share $0.49” on October 26, 2016. More interesting news about Psychemedics Corp. (NASDAQ:PMD) were released by: Prnewswire.com and their article: “Psychemedics Corporation Expands Board Of Directors” published on September 17, 2015 as well as Prnewswire.com‘s news article titled: “Psychemedics Corp To Compete For Brazil Professional Driver Required Hair Drug …” with publication date: December 03, 2013.
PMD Company Profile
Psychemedics Corporation (Psychemedics), incorporated on September 24, 1986, provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Firm operates in drug testing services segment. The Firm is in the business of performing drug testing and reporting the results thereof. The Company’s drug testing services include training for collection of samples and storage of positive samples for its clients for an agreed-upon fee per unit tested of samples. The Company’s primary application of its technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.